HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

valsartan (Vals)

angiotensin II receptor antagonist

Also Known As:

Vals; Provas; Miten; Diovan; Aventis brand of valsartan; CEPA brand of valsartan; CGP 48933; Esteve brand of valsartan; Kalpress; Lacer brand of valsartan; N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine; Nisis; Novartis brand of valsartan; Sanol brand of valsartan; Schwarz brand of valsartan; Tareg; walsartan; L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-

Networked: 1155 relevant articles (164 outcomes, 476 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Califf, Robert M: 36 articles (03/2015 - 08/2003)
2.	Solomon, Scott D: 36 articles (12/2014 - 11/2003)
3.	McMurray, John J V: 35 articles (03/2015 - 11/2003)
4.	Cohn, Jay N: 33 articles (01/2015 - 09/2002)
5.	Velazquez, Eric J: 32 articles (04/2014 - 08/2003)
6.	Pfeffer, Marc A: 30 articles (04/2014 - 08/2003)
7.	Maggioni, Aldo P: 30 articles (11/2013 - 10/2002)
8.	Latini, Roberto: 28 articles (11/2013 - 04/2002)
9.	Tognoni, Gianni: 23 articles (11/2013 - 10/2002)
10.	Anand, Inder S: 19 articles (01/2015 - 03/2003)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2002 - "Thus, invoril and diovan are highly effective and safe drugs for treatment of arterial hypertension of the first and second degree. " 10/01/2010 - "High-dose valsartan is safe and effective in uncomplicated mild-to-moderate hypertension independently of the initial response to a moderate dose. " 01/01/2002 - "Valsartan was found effective in controlling hypertension, also echocardiographic indices of LVH such as interventricular septum and posterior wall thickness were reduced and left ventricular mass decreased significantly. " 01/01/1999 - "Long-term treatment with valsartan resulted in a significant reduction of LVH in patients with essential hypertension." 01/01/1999 - "Long-term treatment with valsartan resulted in a significant reduction of LVH in patients with essential hypertension."
2.	Heart Failure 04/01/2002 - "The Valsartan Heart Failure Trial was designed to determine whether addition of valsartan improved the outcomes of patients receiving standard therapy for heart failure, which in most cases included an ACE inhibitor. " 05/01/2003 - "Valsartan significantly reduced the combined endpoint of mortality and morbidity and improved clinical signs and symptoms in patients with heart failure, if added to prescribed therapy. " 05/01/2008 - "Valsartan improved morbidity rates in the Valsartan Heart Failure Trial (Val-HeFT) despite a reduction in SBP. " 06/01/2009 - "Valsartan improved cardiac function in heart failure rabbits probably via downregulating myocardial CaMK II expression and activity." 09/01/2008 - "Valsartan improved cardiac function in volume and pressure overload induced heart failure rabbits possibly by upregulating expressions of myocardial SERCA2, PKA and downregulating expression of myocardial PP1alpha."
3.	Proteinuria 07/01/2011 - "Valsartan treatment caused a significant reduction in proteinuria from baseline throughout the study in patients with each genotype of the ACE, AGT and TGFB1 genes. " 01/01/2009 - "The results showed that valsartan was more effective in decreasing the levels of proteinuria in hypertensive patients with proteinuria at an early stage of nephropathy. " 12/01/2004 - "Furthermore, valsartan exerted protective effects also when given after established proteinuria. " 05/01/2006 - "There was a significant decrease in mean rate of GFR decrease in the valsartan-treated group (-5.62 +/- 6.79 mL/min/y [-0.09 +/- 0.11 mL/s/y]) compared with the placebo group (-6.98 +/- 6.17 mL/min/y [-0.12 +/- 0.10 mL/s/y]) throughout the study period after adjustment for average blood pressure and proteinuria (P = 0.014). " 06/01/2014 - "These results support the hypothesis that higher doses of valsartan are required to optimize proteinuria reduction and glomerulosclerosis amelioration. "
4.	Myocardial Infarction 06/01/2007 - "Periostin expression was significantly increased in infarcted myocardium (P<0.05), and treatment with valsartan significantly attenuated it at 4 weeks after myocardial infarction (P<0.05), accompanied by a significant improvement in cardiac dysfunction (P<0.05). " 10/01/2010 - "Research performance improved during the VALsartan In Acute myocardial iNfarcTion consistent with a "learning curve". " 03/01/2015 - "We examined the association of sex with clinical characteristics and outcomes in patients following myocardial infarction (MI) in the Valsartan in Acute Myocardial Infarction Trial (VALIANT). " 03/01/2015 - "Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)." 04/01/2014 - "Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)."
5.	Diabetic Nephropathies (Diabetic Nephropathy) 09/01/2003 - "To determine the efficacy of AT1 receptor antagonist (valsartan) in decreasing of urinary excretion of albumin in normotensive patients with type 1 diabetes and incipient diabetic nephropathy (DN). " 07/01/2012 - "Valsartan may reduce HIF-1α-mediated gene activation and consequently improve kidney damage in diabetic nephropathy rats." 01/01/2011 - "In conclusion, these data indicate that the efficacy on BP-lowering does not depend on administration timing of valsartan in patients with diabetic nephropathy." 09/01/2009 - "Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model." 09/01/2002 - "Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy."

Related Drugs and Biologics

1.	Amlodipine (Norvasc)
2.	Hydrochlorothiazide (Esidrix)
3.	aliskiren
4.	Losartan (Cozaar)
5.	Enalapril
6.	Angiotensins
7.	olmesartan
8.	valsartan drug combination amlodipine
9.	candesartan
10.	Angiotensin Receptors (Angiotensin II Receptor)

Related Therapies and Procedures

1.	Chronotherapy
2.	Stents
3.	Ligation
4.	Laparotomy
5.	Intravenous Injections